|
Rheumatoid Arthritis
Citations 301-310 of 841 total displayed.
|
Past content
(since Feb 2000):
|
- BASIC SCIENCE
The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis
- M. Pierer, F. Brentano, J. Rethage, U. Wagner, H. Hantzschel, R. E. Gay, S. Gay, and D. Kyburz
Rheumatology 2007; 46: 1063-1070.
[Abstract]
[Full Text]
[ Supplementary Data ]
- BASIC SCIENCE
Synovial fibronectin fragmentation and domain expressions in relation to rheumatoid arthritis progression
- M. Przybysz, K. Borysewicz, J. Szechinski, and I. Katnik-Prastowska
Rheumatology 2007; 46: 1071-1075.
[Abstract]
[Full Text]
- CLINICAL
Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients
- A. L. Feitsma, R. E. M. Toes, A. B. Begovich, A. P. Chokkalingam, R. R. P. de Vries, T. W. J. Huizinga, and A. H. M. van der Helm-van Mil
Rheumatology 2007; 46: 1092-1095.
[Abstract]
[Full Text]
- CLINICAL
Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome
- L. Fardet, J. Cabane, A. Kettaneh, C. Lebbé, and A. Flahault
Rheumatology 2007; 46: 1102-1106.
[Abstract]
[Full Text]
- CLINICAL
Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis
- F. Del Porto, B. Laganà, S. Lai, I. Nofroni, F. Tinti, M. Vitale, E. Podestà, A. P. Mitterhofer, and R. D’Amelio
Rheumatology 2007; 46: 1111-1115.
[Abstract]
[Full Text]
- CLINICAL
A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases
- Michael H. Weisman, Harold E. Paulus, Francis X. Burch, Alan J. Kivitz, Joshua Fierer, Meleana Dunn, David R. Kerr, Wayne Tsuji, and Scott W. Baumgartner
Rheumatology 2007; 46: 1122-1125.
[Abstract]
[Full Text]
- CLINICAL
The efficacy of inhibiting tumour necrosis factor  and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons
- R. Nixon, N. Bansback, and A. Brennan
Rheumatology 2007; 46: 1140-1147.
[Abstract]
[Full Text]
- CLINICAL
Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis
- C. A. E. Walsh, P. Minnock, C. Slattery, N. Kennedy, F. Pang, D. J. Veale, B. Bresnihan, and O. FitzGerald
Rheumatology 2007; 46: 1148-1152.
[Abstract]
[Full Text]
- CLINICAL
Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders
- M. H. Buch, S. J. Bingham, D. Bryer, and P. Emery
Rheumatology 2007; 46: 1153-1156.
[Abstract]
[Full Text]
- CLINICAL
Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis
- S. Bernatsky, M. Hudson, and S. Suissa
Rheumatology 2007; 46: 1157-1160.
[Abstract]
[Full Text]
|
|
